Abstract | OBJECTIVES: Since the introduction of endoscopic retrograde cholangiopancreatology (ERCP) in clinical use, pancreatitis has become a common complication of ERCP. Octreotide is an inhibitor of pancreatic enzyme secretions. Several studies have evaluated the effect of octreotide on the incidence of clinical pancreatitis after ERCP, but with different results. The aim was to determine the efficacy of prophylactic administration of octreotide for the prevention of post-ERCP pancreatitis (PEP) and hyperamylasemia. METHODS: RESULTS: The overall incidence of acute pancreatitis was 3.85%; this included 2.42% (10/414) in the octreotide group and 5.26% (22/418) in the control group (P = 0.046). The overall incidence of hyperamylasemia was 14.9%; 12.32% (51/414) in the octreotide group and 17.46% (73/418) in the control group (P = 0.041). No side effects were found. CONCLUSION:
|
Authors | Zhao-Shen Li, Xue Pan, Wen-Jun Zhang, Biao Gong, Fa-Chao Zhi, Xue-Gang Guo, Pei-Ming Li, Zhi-Ning Fan, Wen-Sheng Sun, Yun-Zhi Shen, Shu-Ren Ma, Wei-Fen Xie, Min-Hu Chen, Yan-Qing Li |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 102
Issue 1
Pg. 46-51
(Jan 2007)
ISSN: 0002-9270 [Print] United States |
PMID | 17266687
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Gastrointestinal Agents
- Placebos
- Octreotide
|
Topics |
- China
(epidemiology)
- Cholangiopancreatography, Endoscopic Retrograde
(adverse effects)
- Female
- Gastrointestinal Agents
(therapeutic use)
- Humans
- Hyperamylasemia
(epidemiology, etiology, prevention & control)
- Incidence
- Male
- Middle Aged
- Octreotide
(therapeutic use)
- Pancreatitis
(epidemiology, etiology, prevention & control)
- Placebos
- Risk Factors
- Treatment Outcome
|